Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GLYCANC

Financiado

Cerrado

Matrix glycans as multifunctional pathogenesis factors and therapeutic targets i...

Matrix glycans as multifunctional pathogenesis factors and therapeutic targets in cancer Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also with... ver más

30/06/2019

567K€

Presupuesto del proyecto: 567K€

Líder del proyecto

UNIVERSITAET MUENSTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 16 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-06-30

MSCA-RISE-2014: Marie Skłodowska-Curie Research and...

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

103.50K€ | Lider

45.00K€ | Participante

CAIRO UNIVERSITY

SERENDIP GMBH

4.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SECRET Exploitation of the SECRETory pathway for cancer therapy to... 4M€ Cerrado

RTI2018-098968-B-I00 NUEVOS FACTORES IMPLICADOS EN EL FENOTIPO PSEUDO-ENDOTELIAL... 242K€ Cerrado

PID2019-106099RB-C42 MICROGELES BIOMIMETICOS PARA EL ESTUDIO DEL MICROENTORNO DEL... 151K€ Cerrado

PID2021-123013OB-I00 BIOMATERIALES BIOINSPIRADOS PARA MODELAR LA INTERACCION CELU... 157K€ Cerrado

CarboMed Development of carbohydrate based anticancer agents 150K€ Cerrado

DEGLYCAR-T Engineering CAR-T cells to overcome glycosylation-driven tum... 2M€ Cerrado

Duración del proyecto: 55 meses Fecha Inicio: 2014-11-25
Fecha Fin: 2019-06-30

Líder del proyecto

UNIVERSITAET MUENSTER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 567K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) – structurally diverse carbohydrates of the extracellular matrix and cell surfaces - have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell-cell as well as matrix adhesion. Importantly, their expression is dysregulated in numerous tumor entities, and has been shown to modulate each of the hallmarks of cancer as defined by Hanahan and Weinberg (Cell 2011). We hypothesize that dysregulated function of PGs and GAGs simultaneously affects all molecular steps towards cancer metastasis as a general principle applicable to multiple tumor entities. Pharmacological modulation of their function thus emerges as an attractive multitargeted antitumoral approach which simultaneously acts at multiple levels of disease progression. Besides providing extensive knowledge transfer and training for researchers, the combined expertise of the GLYCANC consortium aims at performing a detailed structural analysis of PG and GAG glycans in disease using state-of-the art methodology, analysing their regulation via epigenetic mechanisms and microRNAs, and elucidating molecular mechanisms underlying aberrant PG and GAG function. GLYCANC will lead to a deeper understanding of glycan structures and glycan-dependent mechanisms promoting cancer progression, providing the basis for rational multitargeted anticancer approaches.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores